15 results on '"Kim, Ho Sung"'
Search Results
2. Deep learning-based metastasis detection in patients with lung cancer to enhance reproducibility and reduce workload in brain metastasis screening with MRI: a multi-center study
- Author
-
Park, Yae Won, Park, Ji Eun, Ahn, Sung Soo, Han, Kyunghwa, Kim, NakYoung, Oh, Joo Young, Lee, Da Hyun, Won, So Yeon, Shin, Ilah, Kim, Ho Sung, and Lee, Seung-Koo
- Published
- 2024
- Full Text
- View/download PDF
3. Repeatability of amide proton transfer–weighted signals in the brain according to clinical condition and anatomical location
- Author
-
Lee, Jung Bin, Park, Ji Eun, Jung, Seung Chai, Jo, Youngheun, Kim, Donghyun, Kim, Ho Sung, Choi, Choong-Gon, Kim, Sang Joon, and Kang, Dong-Wha
- Published
- 2020
- Full Text
- View/download PDF
4. Tumor habitat analysis by magnetic resonance imaging distinguishes tumor progression from radiation necrosis in brain metastases after stereotactic radiosurgery.
- Author
-
Lee, Da Hyun, Park, Ji Eun, Kim, NakYoung, Park, Seo Young, Kim, Young-Hoon, Cho, Young Hyun, and Kim, Ho Sung
- Subjects
MAGNETIC resonance imaging ,STEREOTACTIC radiosurgery ,CANCER invasiveness ,BRAIN tumors ,RECEIVER operating characteristic curves ,BLOOD volume - Abstract
Objectives: The identification of viable tumor after stereotactic radiosurgery (SRS) is important for future targeted therapy. This study aimed to determine whether tumor habitat on structural and physiologic MRI can distinguish viable tumor from radiation necrosis of brain metastases after SRS. Method: Multiparametric contrast-enhanced T1- and T2-weighted imaging, apparent diffusion coefficient (ADC), and cerebral blood volume (CBV) were obtained from 52 patients with 69 metastases, showing enlarging enhancing masses after SRS. Voxel-wise clustering identified three structural MRI habitats (enhancing, solid low-enhancing, and nonviable) and three physiologic MRI habitats (hypervascular cellular, hypovascular cellular, and nonviable). Habitat-based predictors for viable tumor or radiation necrosis were identified by logistic regression. Performance was validated using the area under the curve (AUC) of the receiver operating characteristics curve in an independent dataset with 24 patients. Results: None of the physiologic MRI habitats was indicative of viable tumor. Viable tumor was predicted by a high-volume fraction of solid low-enhancing habitat (low T2-weighted and low CE-T1-weighted values; odds ratio [OR] 1.74, p <.001) and a low-volume fraction of nonviable tissue habitat (high T2-weighted and low CE-T1-weighted values; OR 0.55, p <.001). Combined structural MRI habitats yielded good discriminatory ability in both development (AUC 0.85, 95% confidence interval [CI]: 0.77–0.94) and validation sets (AUC 0.86, 95% CI:0.70–0.99), outperforming single ADC (AUC 0.64) and CBV (AUC 0.58) values. The site of progression matched with the solid low-enhancing habitat (72%, 8/11). Conclusion: Solid low-enhancing and nonviable tissue habitats on structural MRI can help to localize viable tumor in patients with brain metastases after SRS. Key Points: • Structural MRI habitats helped to differentiate viable tumor from radiation necrosis. • Solid low-enhancing habitat was most helpful to find viable tumor. • Providing spatial information, the site of progression matched with solid low-enhancing habitat. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Low conductivity on electrical properties tomography demonstrates unique tumor habitats indicating progression in glioblastoma.
- Author
-
Park, Ji Eun, Kim, Ho Sung, Kim, NakYoung, Kim, Young-Hoon, Kim, Jeong Hoon, Kim, Eunju, Hwang, Jinwoo, and Katscher, Ulrich
- Subjects
- *
ELECTRIC conductivity , *ELECTRICAL conductivity measurement , *BRAIN tumors , *GLIOBLASTOMA multiforme , *TOMOGRAPHY , *HABITATS - Abstract
Objectives: Tissue conductivity measurements made with electrical properties tomography (EPT) can be used to define temporal changes in tissue habitats on longitudinal multiparametric MRI. We aimed to demonstrate the added insights for identifying tumor habitats obtained by including EPT with diffusion- and perfusion-weighted MRI, and to evaluate the use of these tumor habitats for determining tumor treatment response in post-treatment glioblastoma. Methods: Tumor habitats were developed from EPT, diffusion-weighted, and perfusion-weighted MRI in 60 patients with glioblastoma who underwent concurrent chemoradiotherapy. Voxels from EPT, apparent diffusion coefficient (ADC), and cerebral blood volume (CBV) maps were clustered into habitats, and each habitat was serially examined to assess its temporal change. The usefulness of temporal changes in tumor habitats for diagnosing tumor progression and treatment-related change was investigated using logistic regression. The performance of significant predictors was measured using the area under the curve (AUC) from receiver-operating-characteristics analysis with 1000-fold bootstrapping. Results: Five tumor habitats were identified, and of these, the hypervascular cellular habitat (odds ratio [OR] 5.45; 95% CI, 1.75–31.42; p =.02), hypovascular low conductivity habitat (OR 2.00; 95% CI, 1.45–3.05; p <.001), and hypovascular intermediate habitat (OR 1.57; 95% CI, 1.18–2.30; p =.006) were predictive of tumor progression. Low EPT and low CBV reflected a unique hypovascular low conductivity habitat that showed the highest diagnostic performance (AUC 0.86; 95% CI, 0.76–0.96). The combined habitats showed high performance (AUC 0.90; 95% CI, 0.82–0.98) in the differentiation of tumor progression from treatment-related change. Conclusion: EPT reveals low conductivity habitats that can improve the diagnosis of tumor progression in post-treatment glioblastoma. Key Points: • Electrical properties tomography (EPT) demonstrated lower conductivity in tumor progression than in treatment-related change. • EPT allowed identification of a unique hypovascular low conductivity habitat when combined with cerebral blood volume mapping. • Tumor habitats with a hypovascular low conductivity habitat, hypervascular cellular habitat, and hypovascular intermediate habitat yielded high diagnostic performance for diagnosing tumor progression. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Spatiotemporal habitats from multiparametric physiologic MRI distinguish tumor progression from treatment-related change in post-treatment glioblastoma.
- Author
-
Kim, Minjae, Park, Ji Eun, Kim, Ho Sung, Kim, NaKyoung, Park, Seo Young, Kim, Young-Hoon, and Kim, Jeong Hoon
- Subjects
CANCER invasiveness ,BRAIN tumors ,RECEIVER operating characteristic curves ,GLIOBLASTOMA multiforme ,DIFFUSION magnetic resonance imaging ,HABITATS - Abstract
Objectives: We aimed to develop multiparametric physiologic MRI-based spatial habitats and to evaluate whether temporal changes in these habitats help to distinguish tumor progression from treatment-related change in post-treatment glioblastoma. Methods: This retrospective, single-institution study included patients with glioblastoma treated by concurrent chemoradiotherapy who had newly developed or enlarging, measurable contrast-enhancing mass. Contrast-enhancing mass was divided into three spatial habitats by K-means clustering of voxel-wise ADC and CBV values. Temporal changes of these habitats between two consecutive examinations prior to the diagnosis of tumor progression or treatment-related change were assessed. Predictors were selected using logistic regression and the performance was measured with an area under the receiver operating characteristics curve (AUC). Spatiotemporal habitats were further analyzed for correlation with the site of tumor progression. Results: There were 75 patients (mean, 58 years; range, 26−81 years; 43 men) with 48 cases of tumor progression and 39 cases of treatment-related change including 12 patient overlaps at different time points. Three spatial habitats of hypervascular cellular, hypovascular cellular, and nonviable tissue were identified. Increase in the hypervascular cellular (OR 4.55, p =.002) and hypovascular cellular habitat (OR 1.22, p <.001) was predictive of tumor progression. Combination of spatiotemporal habitats yielded a high diagnostic performance with an AUC of 0.89 (95% CI, 0.87–0.92). An increase in hypovascular cellular habitat predicted the site of tumor progression in 84% [21/25] of cases with tumor progression. Conclusions: Temporal changes in spatial habitats derived from multiparametric physiologic MRI provided diagnostic value in distinguishing tumor progression from treatment-related change and predicted site of tumor progression in post-treatment glioblastoma. Key Points: • In post-treatment glioblastoma, three spatial habitats of hypervascular cellular, hypovascular cellular, and nonviable tissue were identified, and an increase in the hypervascular cellular (OR 4.55, p =.002) and hypovascular cellular habitat (OR 1.22, p <.001) was predictive of tumor progression. • Combination of spatiotemporal habitats yielded a high diagnostic performance with an AUC of 0.89 (95% CI, 0.87–0.92). • An increase in hypovascular cellular habitat predicted the site of tumor progression in 84% (21/25) of cases with tumor progression. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. The T2-FLAIR mismatch sign as a predictor of IDH-mutant, 1p/19q-noncodeleted lower-grade gliomas: a systematic review and diagnostic meta-analysis.
- Author
-
Park, Sang Ik, Suh, Chong Hyun, Guenette, Jeffrey P., Huang, Raymond Y., and Kim, Ho Sung
- Subjects
BRAIN tumors ,GLIOMAS ,FORECASTING ,SENSITIVITY & specificity (Statistics) ,ISOCITRATE dehydrogenase ,STATISTICAL correlation - Abstract
Objectives: To evaluate the diagnostic performance of the T2-FLAIR mismatch sign for prediction of isocitrate dehydrogenase (IDH)-mutant, 1p/19q-noncodeleted lower-grade gliomas (LGGs) and review studies with false positive results. Methods: The MEDLINE and EMBASE databases were searched up to March 13, 2020, to identify articles reporting the diagnostic performance of the T2-FLAIR mismatch sign for prediction of IDH-mutant, 1p/19q-noncodeleted LGGs (IDHmut-Noncodel) using the search terms (T2 FLAIR mismatch). Pooled sensitivity, specificity, and correlation coefficient for interobserver agreement were calculated. Results: Twelve studies including a total of 1053 patients were included. The median age was 43 (median; range, 14–56). The pooled sensitivity and specificity were 42% (95% CI, 28–58%) and 100% (95% CI, 88–100%), respectively. According to the HSROC curve, the area under the curve was 0.77 (95% CI, 0.73–0.80). Considerable heterogeneity was possible among the studies in terms of both sensitivity and specificity. A threshold effect was suggested and was considered to explain most of the heterogeneity. Four studies reported false positive results for the T2-FLAIR mismatch sign, including dysembryoplastic neuroepithelial tumor, pediatric-type gliomas, and non-neoplastic lesions. The 2 original articles with false positive results showed the highest sensitivities among the 10 studies included in the quantitative analysis, supporting the probability of the threshold effect. The pooled correlation coefficient was 0.87 (95% CI, 0.73–0.94). Conclusions: The T2-FLAIR mismatch sign had a high specificity and interobserver agreement for the prediction of IDHmut-Noncodel. However, the sign demonstrated low sensitivity, and a few studies with false positive cases were also reported. Key Points: • The pooled sensitivity and specificity of the T2-FLAIR mismatch sign for prediction of IDH-mutant, 1p/19q-noncodeleted lower-grade gliomas were 42% and 100%, respectively. • Four studies reported false positive results. • The pooled correlation coefficient was 0.87, suggesting almost perfect interobserver agreement. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. Deep-learned time-signal intensity pattern analysis using an autoencoder captures magnetic resonance perfusion heterogeneity for brain tumor differentiation.
- Author
-
Park, Ji Eun, Kim, Ho Sung, Lee, Junkyu, Cheong, E.-Nae, Shin, Ilah, Ahn, Sung Soo, and Shim, Woo Hyun
- Subjects
- *
DEEP learning , *BRAIN tumors , *IMAGE processing , *MAGNETIC resonance imaging , *TUMOR diagnosis , *ARTIFICIAL neural networks , *LYMPHOMAS - Abstract
Current image processing methods for dynamic susceptibility contrast (DSC) magnetic resonance imaging (MRI) do not capture complex dynamic information of time-signal intensity curves. We investigated whether an autoencoder-based pattern analysis of DSC MRI captured representative temporal features that improves tissue characterization and tumor diagnosis in a multicenter setting. The autoencoder was applied to the time-signal intensity curves to obtain representative temporal patterns, which were subsequently learned by a convolutional neural network. This network was trained with 216 preoperative DSC MRI acquisitions and validated using external data (n = 43) collected with different DSC acquisition protocols. The autoencoder applied to time-signal intensity curves and clustering obtained nine representative clusters of temporal patterns, which accurately identified tumor and non-tumoral tissues. The dominant clusters of temporal patterns distinguished primary central nervous system lymphoma (PCNSL) from glioblastoma (AUC 0.89) and metastasis from glioblastoma (AUC 0.95). The autoencoder captured DSC time-signal intensity patterns that improved identification of tumoral tissues and differentiation of tumor type and was generalizable across centers. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
9. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
- Author
-
Lee, Min Kyoung, Park, Ji Eun, Jo, Youngheun, Park, Seo Young, Kim, Sang Joon, and Kim, Ho Sung
- Subjects
OLIGODENDROGLIOMAS ,RECEIVER operating characteristic curves ,REGRESSION analysis ,DIFFUSION magnetic resonance imaging ,BLOOD volume ,CHROMOSOMES ,GENETIC mutation ,GLIOMAS ,MAGNETIC resonance imaging ,BRAIN tumors ,RESEARCH funding ,OXIDOREDUCTASES ,TUMOR grading - Abstract
Objectives: A combination of T2/FLAIR mismatch sign and advanced imaging parameters may improve the determination of molecular subtypes of diffuse lower-grade glioma. We assessed the diagnostic value of adding the apparent diffusion coefficient (ADC) and cerebral blood volume (CBV) to the T2/FLAIR mismatch sign for differentiation of the IDH mutation or 1p/19q codeletion.Materials and Methods: Preoperative conventional, diffusion-weighted, and dynamic susceptibility contrast imaging were performed on 110 patients with diffuse lower-grade gliomas. The study population was classified into three groups using molecular subtype, namely IDH mutation and 1p/19q codeletion (IDHmut-Codel), IDH wild type (IDHwt) and IDH mutation and no 1p/19q codeletion (IDHmut-Noncodel). T2/FLAIR mismatch sign and the histogram parameters of apparent diffusion coefficient (ADC) and normalised cerebral blood volume (nCBV) values were assessed. A multivariate logistic regression model was constructed to distinguish IDHmut-Noncodel from IDHmut-Codel and IDHwt and from IDHwt, and the performance was compared with that of single parameters using the area under the receiver operating characteristics curve (AUC).Results: Positive visual T2/FLAIR mismatch sign and higher nCBV skewness were significant variables to distinguish IDHmut-Noncodel from the other two groups (AUC, 0.88; 95% CI, 0.81-0.96). A lower ADC10 was a significant variable for distinguishing IDHmut-Noncodel from the IDHwt group (AUC, 0.75; 95% CI, 0.62-0.89). Adding ADC or CBV histogram parameters to T2/FLAIR mismatch sign improved performance in distinguishing IDHmut-Noncodel from the other two groups (AUC 0.882 vs. AUC 0.810) or from IDHwt (AUC 0.923 vs. AUC 0.868).Conclusions: The combination of the T2/FLAIR mismatch sign with ADC or CBV histogram parameters can improve the identification of IDHmut-Noncodel diffuse lower-grade gliomas, which can be easily applied in clinical practice.Key Points: • The combination of the T2/FLAIR mismatch sign with the ADC or CBV histogram parameters can improve the identification of IDHmut-Noncodel diffuse lower-grade gliomas. • The multivariable model showed a significantly better performance for distinguishing the IDHmut-Noncodel group from other diffuse lower-grade gliomas than the T2/FLAIR mismatch sign alone or any single parameter. • The IDHmut-Noncodel type was associated with intermediate treatment outcomes; therefore, the identification of IDHmut-Noncodel diffuse lower-grade gliomas could be helpful for determining the clinical approach. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
10. Prognostic relevance of gemistocytic grade II astrocytoma: gemistocytic component and MR imaging features compared to non-gemistocytic grade II astrocytoma.
- Author
-
Heo, Young, Park, Ji, Kim, Ho, Lee, Ji, Nam, Soo, Jung, Seung, Choi, Choong, Kim, Sang, Heo, Young Jin, Park, Ji Eun, Kim, Ho Sung, Lee, Ji Ye, Nam, Soo Jeong, Jung, Seung Chai, Choi, Choong Gon, and Kim, Sang Joon
- Subjects
ASTROCYTOMAS ,TUMOR grading ,DISEASE progression ,TUMORS ,HISTOPATHOLOGY ,CONTRAST-enhanced magnetic resonance imaging ,PROGNOSIS ,MAGNETIC resonance imaging ,BRAIN tumors ,COMPARATIVE studies ,GLIOMAS ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,NUCLEAR magnetic resonance spectroscopy ,RESEARCH ,TIME ,EVALUATION research ,RETROSPECTIVE studies - Abstract
Objectives: To determine if gemistocytic grade II astrocytoma (GemA) and its MR imaging characteristics are associated with a shorter time-to-progression (TTP) compared with non-gemistocytic grade II astrocytoma (non-GemA).Materials and Methods: We enrolled 78 patients who were followed up more than 5 years (29 pathologically proven GemA and 49 non-GemA) during a 10-year period. Contrast-enhanced T1-weighted, diffusion-weighted imaging (DWI), dynamic susceptibility contrast (DSC), and MR spectroscopy (MRS) and clinical data were retrospectively reviewed. Clinical and MR imaging features were analyzed as possible prognostic factors of high-grade transformation, and multivariate analysis of TTP was performed using Cox proportional modeling.Results: GemA showed more frequent high-grade features than non-GemA, including diffusion restriction (P < .001), increased choline/creatine (P = .02), and increased choline/NAA ratio (P = .015). Patients with GemA had a significantly shorter median TTP (53.1 vs 68 months; P < .001). A gemistocytic histopathology (hazard ratio = 3.42; P = .015) and low ADC (hazard ratio = 3.61; P = .001) were independently associated with a shorter TTP.Conclusions: GemA can present with MR imaging findings mimicking high-grade glioma at initial diagnosis and transforms to high-grade disease earlier than non-GemA. Low ADC on DWI might be useful in stratifying the risk of progression in patients with grade II astrocytoma.Key Points: • Gemistocytic grade II astrocytoma (GemA) showed more frequent high-grade features than non-GemA. • Patients with GemA had a significantly shorter median TTP than non-GemA. • Gemistocytic histopathology and low ADC were independently associated with shorter TTP. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
11. Different diagnostic values of imaging parameters to predict pseudoprogression in glioblastoma subgroups stratified by MGMT promoter methylation.
- Author
-
Yoon, Ra, Kim, Ho, Paik, Wooyul, Shim, Woo, Kim, Sang, Kim, Jeong, Yoon, Ra Gyoung, Kim, Ho Sung, Shim, Woo Hyun, Kim, Sang Joon, and Kim, Jeong Hoon
- Subjects
GLIOBLASTOMA multiforme ,DNA methyltransferases ,METHYLATION ,MAGNETIC resonance imaging ,CHEMORADIOTHERAPY ,DIAGNOSIS ,BRAIN tumors ,DNA ,ENZYMES ,GENES ,GLIOMAS ,PHARMACOKINETICS ,PROTEINS ,RETROSPECTIVE studies ,RECEIVER operating characteristic curves ,DISEASE progression ,DNA methylation - Abstract
Objectives: The aim of this study was to determine whether diffusion and perfusion imaging parameters demonstrate different diagnostic values for predicting pseudoprogression between glioblastoma subgroups stratified by O6-mythylguanine-DNA methyltransferase (MGMT) promoter methylation status.Methods: We enrolled seventy-five glioblastoma patients that had presented with enlarged contrast-enhanced lesions on magnetic resonance imaging (MRI) one month after completing concurrent chemoradiotherapy and undergoing MGMT promoter methylation testing. The imaging parameters included 10 or 90 % histogram cutoffs of apparent diffusion coefficient (ADC10), normalized cerebral blood volume (nCBV90), and initial area under the time signal-intensity curve (IAUC90). The results of the areas under the receiver operating characteristic curve (AUCs) with cross-validation were compared between MGMT methylation and unmethylation groups.Results: MR imaging parameters demonstrated a trend toward higher accuracy in the MGMT promoter methylation group than in the unmethylation group (cross-validated AUCs = 0.70-0.95 and 0.56-0.87, respectively). The combination of MGMT methylation status with imaging parameters improved the AUCs from 0.70 to 0.75-0.90 for both readers in comparison with MGMT methylation status alone. The probability of pseudoprogression was highest (95.7 %) when nCBV90 was below 4.02 in the MGMT promoter methylation group.Conclusions: MR imaging parameters could be stronger predictors of pseudoprogression in glioblastoma patients with the methylated MGMT promoter than in patients with the unmethylated MGMT promoter.Key Points: • The glioblastoma subgroup was stratified according to MGMT promoter methylation status. • Diagnostic values of diffusion and perfusion parameters for predicting pseudoprogression were compared. • Imaging parameters showed higher diagnostic accuracy in the MGMT promoter methylation group. • Imaging parameters were independent to MGMT promoter methylation status for predicting pseudoprogression. • Imaging biomarkers might demonstrate different diagnostic values according to MGMT promoter methylation. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
12. Added value of amide proton transfer imaging to conventional and perfusion MR imaging for evaluating the treatment response of newly diagnosed glioblastoma.
- Author
-
Park, Kye, Kim, Ho, Park, Ji, Shim, Woo, Kim, Sang, Smith, Seth, Park, Kye Jin, Kim, Ho Sung, Park, Ji Eun, Shim, Woo Hyun, Kim, Sang Joon, and Smith, Seth A
- Subjects
PROTON transfer reactions ,MAGNETIC resonance imaging ,GLIOBLASTOMA multiforme ,GLIOBLASTOMA multiforme treatment ,CHEMORADIOTHERAPY ,PATIENTS ,BRAIN tumor treatment ,GLIOMA treatment ,AMIDES ,BRAIN tumors ,COMPARATIVE studies ,GLIOMAS ,RESEARCH methodology ,MEDICAL cooperation ,PROTONS ,RESEARCH ,EVALUATION research ,TREATMENT effectiveness ,CONTRAST media ,RECEIVER operating characteristic curves - Abstract
Objectives: To determine the added value of amide proton transfer (APT) imaging to conventional and perfusion MRI for differentiating tumour progression (TP) from the treatment-related effect (TE) in patients with post-treatment glioblastomas.Methods: Sixty-five consecutive patients with enlarging contrast-enhancing lesions following concurrent chemoradiotherapy were assessed using contrast-enhanced T1-weighted MRI (CE-T1WI), 90th percentile histogram parameters of normalized cerebral blood volume (nCBV90) and APT asymmetry value (APT90). Diagnostic performance was determined using the area under the receiver operating characteristic curve (AUC) and cross validations.Results: There were statistically significant differences in the mean APT90 between the TP and the TE groups (3.87-4.01 % vs. 1.38-1.41 %; P < .001). Compared with CE-T1WI alone, the addition of APT90 to CE-T1WI significantly improved cross-validated AUC from 0.58-0.74 to 0.89-0.91 for differentiating TP from TE. The combination of CE-T1WI, nCBV90 and APT90 resulted in greater diagnostic accuracy for differentiating TP from TE than the combination of CE-T1WI and nCBV90 (cross-validated AUC, 0.95-0.97 vs. 0.84-0.91). The inter-reader agreement between the expert and trainee was excellent for the measurements of APT90 (intraclass correlation coefficient, 0.94).Conclusion: Adding APT imaging to conventional and perfusion MRI improves the diagnostic performance for differentiating TP from TE.Key Points: • APT imaging could provide a reliable distinction between TP and TE • Adding APT imaging to CE-T1WI improved the diagnostic accuracy versus CE-T1WI alone • Multimodal imaging using CE-T1WI, perfusion and APT imaging led to accurate diagnosis • The inter-reader agreement of APT histogram parameters was excellent. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
13. Apparent diffusion coefficient parametric response mapping MRI for follow-up of glioblastoma.
- Author
-
Yoon, Ra, Kim, Ho, Kim, Dae, Hong, Gil, Kim, Sang, Yoon, Ra Gyoung, Kim, Ho Sung, Kim, Dae Yoon, Hong, Gil Sun, and Kim, Sang Joon
- Subjects
GLIOBLASTOMA multiforme treatment ,MAGNETIC resonance imaging of the brain ,DIFFUSION coefficients ,HISTOGRAMS ,RECEIVER operating characteristic curves ,BRAIN tumor treatment ,GLIOMA treatment ,BRAIN tumors ,BRAIN mapping ,GLIOMAS ,LONGITUDINAL method ,MAGNETIC resonance imaging ,RESEARCH evaluation ,TREATMENT effectiveness ,RETROSPECTIVE studies - Abstract
Objectives: To determine the diagnostic superiority of parametric response mapping of apparent diffusion coefficient (ADCPR) for predicting glioblastoma treatment response, compared to single time point measurement.Methods: Fifty post-treatment glioblastoma patients were enrolled. ADCPR was calculated from serial apparent diffusion coefficient (ADC) maps acquired before and at the time of first detection of an enlarged contrast-enhancing lesion on voxel-by-voxel basis. The percentage-decrease in ADCPR and tenth percentile histogram cutoff value of ADC (ADC10) were compared at subsequent 3-month and 1-year follow-ups.Results: The percentage-decrease in ADCPR was significantly higher in the progression group (mean = 33.2-38.3 %) than in the stable-response group (mean = 9.7 %) at 3 months follow-up (corrected p < 0.001 for both readers). ADCPR significantly improved area under the receiver operating characteristic curve from 0.67 to 0.88 (corrected p = 0.037) and from 0.70 to 0.92 (corrected p = 0.020) for both readers, respectively, compared to ADC10 at 3-month follow-up, but did not significantly improve at 1-year follow-up. The inter-reader agreement was higher for ADCPR than ADC10 (intraclass correlation coefficient, 0.93 versus 0.86).Conclusion: Voxel-based ADCPR appears to be a superior imaging biomarker than ADC, particularly for predicting early tumour progression in patients with glioblastoma.Key Points: • Treatment response pattern of glioblastoma was evaluated using voxel-based ADCPR and ADC10. • Voxel-based ADCPR was more accurate in predicting treatment response pattern than ADC10. • Inter-reader agreement was higher in ADCPR calculation than in ADC10 calculation. • Voxel-based ADCPR can be a predictor of early treatment response pattern for glioblastoma. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
14. Comparison of Apparent Diffusion Coefficient and Intravoxel Incoherent Motion for Differentiating among Glioblastoma, Metastasis, and Lymphoma Focusing on Diffusion-Related Parameter.
- Author
-
Shim, Woo Hyun, Kim, Ho Sung, Choi, Choong-Gon, and Kim, Sang Joon
- Subjects
- *
DIFFUSION coefficients , *GLIOBLASTOMA multiforme , *PARAMETER estimation , *COMPARATIVE studies , *BRAIN tumors - Abstract
Background and Purpose: Brain tumor cellularity has been assessed by using apparent diffusion coefficient (ADC). However, the ADC value might be influenced by both perfusion and true molecular diffusion, and the perfusion effect on ADC can limit the reliability of ADC in the characterization of tumor cellularity, especially, in hypervascular brain tumors. In contrast, the IVIM technique estimates parameter values for diffusion and perfusion effects separately. The purpose of our study was to compare ADC and IVIM for differentiating among glioblastoma, metastatic tumor, and primary CNS lymphoma (PCNSL) focusing on diffusion-related parameter. Materials and Methods: We retrospectively reviewed the data of 128 patients with pathologically confirmed glioblastoma (n = 55), metastasis (n = 31), and PCNSL (n = 42) prior to any treatment. Two neuroradiologists independently calculated the maximum IVIM-f (fmax) and minimum IVIM-D (Dmin) by using 16 different b-values with a bi-exponential fitting of diffusion signal decay, minimum ADC (ADCmin) by using 0 and 1000 b-values with a mono-exponential fitting and maximum normalized cerebral blood volume (nCBVmax). The differences in fmax, Dmin, nCBVmax, and ADCmin among the three tumor pathologies were determined by one-way ANOVA with multiple comparisons. The fmax and Dmin were correlated to the corresponding nCBV and ADC using partial correlation analysis, respectively. Results: Using a mono-exponential fitting of diffusion signal decay, the mean ADCmin was significantly lower in PCNSL than in glioblastoma and metastasis. However, using a bi-exponential fitting, the mean Dmin did not significantly differ in the three groups. The mean fmax significantly increased in the glioblastomas (reader 1, 0.103; reader 2, 0.109) and the metastasis (reader 1, 0.105; reader 2, 0.107), compared to the primary CNS lymphomas (reader 1, 0.025; reader 2, 0.023) (P < .001 for each). The correlation between fmax and the corresponding nCBV was highest in glioblastoma group, and the correlation between Dmin and the corresponding ADC was highest in primary CNS lymphomas group. Conclusion: Unlike ADC value derived from a mono-exponential fitting of diffusion signal, diffusion-related parametric value derived from a bi-exponential fitting with separation of perfusion effect doesn’t differ among glioblastoma, metastasis, and PCNSL. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
15. Correction to: Low conductivity on electrical properties tomography demonstrates unique tumor habitats indicating progression in glioblastoma.
- Author
-
Park, Ji Eun, Kim, Ho Sung, Kim, NakYoung, Kim, Young-Hoon, Kim, Jeong Hoon, Kim, Eunju, Hwang, Jinwoo, and Katscher, Ulrich
- Subjects
- *
ELECTRIC conductivity , *GLIOBLASTOMA multiforme , *TOMOGRAPHY , *HABITATS , *BRAIN tumors , *TUMORS - Abstract
A Correction to this paper has been published: https://doi.org/10.1007/s00330-021-08065-8 [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.